Clinical Trials Logo
  1. Home
  2. Acute Migraine
  3. NCT02439320

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: — SAMURAI  

Acute Migraine Clinical Trial

Official title:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Clinical Trial Summary

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Clinical Trial Description

Participants will be asked to treat a migraine attack with study drug on an outpatient basis. Participants will be provided with a dosing card containing a dose for initial treatment and a second dose to be used for rescue or recurrence of migraine. Each participant's study participation will consist of a screening visit (Visit 1) with a telephone contact within 7 days to confirm eligibility, a Treatment Period of up to 8 weeks, and an End-of-Study (EoS) visit (Visit 2) within one week (7 days) of treating a single migraine attack. The total time on study is approximately 11 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02439320
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 3
Start date April 2015
Completion date August 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT04153409 - A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine Phase 2
Completed NCT02279082 - DFN-02 Open Label Safety Study in Patients With Acute Migraine Phase 3
Completed NCT04574362 - Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine Phase 3
Completed NCT01973205 - Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine Phase 3
Terminated NCT04089761 - Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents N/A
Completed NCT03631550 - The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine N/A
Completed NCT01267864 - Valproate Versus Ketorolac Versus Metoclopramide Phase 4
Completed NCT05371652 - A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants Phase 3
Completed NCT04218162 - Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean Phase 3
Completed NCT01730326 - Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack Phase 4
Completed NCT04408794 - Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine Phase 2/Phase 3
Completed NCT02745392 - Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine Phase 2/Phase 3
Completed NCT00894556 - A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087) Phase 3
Terminated NCT02185703 - Chordate System S020 Acute Migraine Clinical Investigation N/A
Terminated NCT01680029 - PBASE-system Acute Migraine Clinical Investigation N/A
Completed NCT01358279 - Transcranial Direct Current Stimulation for Migraine Attack N/A
Not yet recruiting NCT01228552 - The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine Phase 3
Completed NCT02684409 - Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine Phase 1
Terminated NCT01112553 - Treximet Migraine Brain Imaging Research Study N/A
Completed NCT01276977 - Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine N/A